483 results match your criteria Asia-Pacific Oncology & Haematology [Journal]


Gender Differences in Cancer Patients' Preferences for Truth-Telling in Taiwan.

Cancer Nurs 2020 Jul 8. Epub 2020 Jul 8.

Author Affiliations: School of Nursing, Chang Gung University, Taoyuan, Taiwan (Ms. Chen and Dr Tang); Psycho-Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan (Dr Fujimori); and Department of Hematology-Oncology, Chang Gung Memorial Hospital, Linkou, Taiwan (Drs Wang and Tang).

Background: There is a lack of studies investigating gender differences in cancer truth-telling, especially from the Asia Pacific countries.

Objective: The aim of this study was to compare preferences for cancer truth-telling between male and female cancer patients in Taiwan.

Methods: We used a quantitative cross-sectional design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NCC.0000000000000856DOI Listing

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.

Liver Cancer 2020 Jun 13;9(3):245-260. Epub 2020 May 13.

Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.

The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) was established on August 31, 2019, in Sapporo, Hokkaido during the 10th Annual APPLE Meeting. This manuscript summarizes the international consensus statements developed at APPLE 2019. Transarterial chemoembolization (TACE) is the only guideline-recommended global standard of care for intermediate-stage HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507370DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325125PMC

The incidence of squamous cell carcinoma of the oral tongue is rising in young non-smoking women: An international multi-institutional analysis.

Oral Oncol 2020 Jul 1;110:104875. Epub 2020 Jul 1.

Central Clinical School, University of Sydney, Parramatta Road, Camperdown, NSW 2050, Australia; Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia. Electronic address:

Purpose: Increasing evidence is accumulating for an alarming rising incidence of oral tongue SCC in a younger cohort, particularly in developed countries. The aim of this study is to analyse the change in incidence of OSCC in patients under the age of 45 in developed nations in the Asia-Pacific region.

Patients And Methods: Population data was extracted from the Australian Cancer Incidence and Mortality 2017 database and National Registry of Diseases Office, Singapore to allow calculation of the incidence in the Australian and Singaporean populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.104875DOI Listing

Dual Challenge of Cancer and COVID-19: Impact on Health Care and Socioeconomic Systems in Asia Pacific.

JCO Glob Oncol 2020 Jun;6:906-912

Department of Radiation Oncology, Nizam's Institute of Medical Sciences, Hyderabad, India.

Coronavirus or COVID-19 is caused by severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic has resulted in social and economic disruption throughout the entire world. Each country is being challenged. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/GO.20.00227DOI Listing

The Past, Present and Future of Literature Pertaining to Betel () Nut: A Citation Analysis.

Subst Use Misuse 2020 ;55(9):1403-1412

Department of Biostatistics, National Drug Dependence Treatment Centre and Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.

Betel (areca) nut has recently received interest from researchers and policy makers for its role as a psychoactive substance. It was historically limited to Asia-pacific region, but with the advent of globalization, it has become an equally challenging public health problem across the globe. Previously published literature can give us valuable insights in terms of historical interest and understanding related to betel nut. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10826084.2019.1660677DOI Listing
January 2020

Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country.

J Cancer Educ 2020 Jun 20. Epub 2020 Jun 20.

Department of Surgery, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia.

There are several treatment options for localized prostate cancer with very similar outcome but vary in terms of technique and side effect profiles and risks. Considering the potential difficulty in choosing the best treatment, a patient decision aid (PDA) is used to help patients in their decision-making process. However, the use and applicability of PDA in a country in Asia Pacific region like Malaysia is still unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13187-020-01801-6DOI Listing

Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.

Hepatol Int 2020 May 23. Epub 2020 May 23.

Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

Background: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide.

Aims: In order to enhance scientific information interflow in the arena of liver diseases in Asia-Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials.

Methods: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia-Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-020-10054-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245190PMC

Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement.

Int J Radiat Oncol Biol Phys 2020 07 14;107(4):618-627. Epub 2020 Apr 14.

Department of Radiation Oncology, University of California San Francisco, San Francisco, California. Electronic address:

Purpose: Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff.

Methods And Materials: A panel of international experts from ASTRO, ESTRO, and select Asia-Pacific countries completed a modified rapid Delphi process. Topics and questions were presented to the group, and subsequent questions were developed from iterative feedback. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2020.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194855PMC

Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore.

Asia Pac J Clin Oncol 2020 Apr 16. Epub 2020 Apr 16.

Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

Next-generation sequencing (NGS)-based diagnostics have demonstrated clinical utility in predicting improved survival benefits with targeted treatment in certain cancer types, and positive cost-benefit in several healthcare systems. However, clinical adoption in Singapore remains low despite commercial availability of these diagnostics. This expert opinion review examines the key challenges to the clinical adoption of NGS-based diagnostics in Singapore, provides recommendations on impactful initiatives to improve adoption, and also offers practical guidance on specific cancer types in which NGS-based diagnostics are appropriate for use in Singapore. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13339DOI Listing

Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study.

BMC Gastroenterol 2020 Apr 6;20(1):88. Epub 2020 Apr 6.

Department of Medicine, Chulalongkorn University, Bangkok, Thailand.

Background: The Gut and Obesity in Asia (GOASIA) Workgroup was formed to study obesity and gastrointestinal diseases in the Asia Pacific region. We aimed to 1) compare the characteristics of elderly (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-020-01240-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137333PMC
April 2020
2.365 Impact Factor

Current Status of "Watch-and-Wait" Rectal Cancer Treatment in Asia-Pacific Countries.

Ann Coloproctol 2020 Apr 31;36(2):70-77. Epub 2020 Jan 31.

Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Purpose: Current acceptance of the watch-and-wait (W&W) approach by surgeons in Asia-Pacific countries is unknown. An international survey was performed to determine status of the W&W approach on behalf of the Asia-Pacific Federation of Coloproctology (APFCP).

Methods: Surgeons in the APFCP completed an Institutional Review Board-approved anonymous e-survey and/or printed letters (for China) containing 19 questions regarding nonsurgical close observation in patients who achieved clinical complete response (cCR) to neoadjuvant chemoradiotherapy (nCRT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3393/ac.2020.01.19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299564PMC

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

Lancet Haematol 2020 Mar 23;7(3):e226-e237. Epub 2020 Jan 23.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Polycythaemia vera is a myeloproliferative neoplasm characterised by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow due to mutations in the Janus kinase 2 (JAK2) gene. Ruxolitinib, a JAK 1 and JAK 2 inhibitor, showed superiority over best available therapy in a phase 2 study in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea. We aimed to compare the long-term safety and efficacy of ruxolitinib with best available therapy in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30207-8DOI Listing

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.

Oral Oncol 2020 Jan 21;102:104526. Epub 2020 Jan 21.

The Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre, 237 Fulham Road, London SW3 6JB, United Kingdom. Electronic address:

Objectives: Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting.

Materials And Methods: A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characteristics, treatment and survival data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2019.104526DOI Listing
January 2020

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.

Cost Eff Resour Alloc 2020 15;18. Epub 2020 Jan 15.

7MSD Kenilworth, Kenilworth, NJ USA.

Background: Pembrolizumab has been shown to improve overall survival (OS) and progression free survival (PFS) compared to ipilimumab in patients with ipilimumab-naïve advanced melanoma; however, there are no published data on the cost-effectiveness for pembrolizumab compared to standard-of-care treatments currently used in Hong Kong for advanced melanoma.

Methods: A partitioned-survival model based on data from a recent randomized phase 3 study (KEYNOTE-006) and meta-analysis was used to derive time in PFS, OS, and post-progression survival for pembrolizumab and chemotherapy, such as dacarbazine (DTIC), temozolomide (TMZ), and the paclitaxel-carboplatin combination (PC). A combination of clinical trial data, published data, results of meta-analysis, and melanoma registry data was used to extrapolate PFS and OS curves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12962-020-0200-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964068PMC
January 2020

Development and Validation of the Asia-Pacific Proximal Colon Neoplasia Risk Score.

Clin Gastroenterol Hepatol 2020 Jan 7. Epub 2020 Jan 7.

Department of Medicine and Therapeutics, The Chinese University of Hong Kong; The Institute of Digestive Disease, The Chinese University of Hong Kong; The State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong. Electronic address:

Background & Aims: Patients found to be at high risk of advanced proximal neoplasia (APN) after flexible sigmoidoscopy screening should be considered for colonoscopy examination. We developed and validated a scoring system to identify persons at risk for APN.

Methods: We collected data from 7954 asymptomatic subjects (age, 50-75 y) who received screening colonoscopy examinations at 14 sites in Asia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2019.12.031DOI Listing
January 2020
7.896 Impact Factor

Improvement of Asia-Pacific colorectal screening score and evaluation of its use combined with fecal immunochemical test.

BMC Gastroenterol 2019 Dec 27;19(1):226. Epub 2019 Dec 27.

Department of Gastroenterology, Key Laboratory of Gut Microbiota Translational Medicine Research, Chinese Academy of Medical Science, Peking Union Medical College Hospital, No.1, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.

Background: The Asia-Pacific Colorectal Screening (APCS) score is effective to screen high-risk groups of advanced colorectal neoplasia (ACN) patients but needs revising and can be combined with the fecal immunochemical test (FIT). This paper aimed to improve the APCS score and evaluate its use with the FIT in stratifying the risk of ACN.

Methods: This prospective and multicenter study enrolled 955 and 1201 asymptomatic Chinese participants to form the derivation and validation set, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-019-1146-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935212PMC
December 2019
2.365 Impact Factor

Colorectal Cancer in Brunei Darussalam: An Overview and Rationale for National Screening Programme.

Asian Pac J Cancer Prev 2019 Dec 1;20(12):3571-3580. Epub 2019 Dec 1.

PAPRBS Institute of Health Sciences, Universiti Brunei Darussalam, Brunei Darussalam.

Colorectal cancer (CRC) is the third most common cancer worldwide after lung and breast cancers, and ranks second in terms of cancer mortality globally. Brunei Darussalam reports high incidence of CRC in the Southeast Asian region and has no formal national screening programme for CRC. Screening for CRC in Brunei Darussalam is offered in an opportunistic fashion for individuals with average or above average risks for CRC, that is, the individual has a positive family history of CRC or neoplasms and is more than 50 years old. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2019.20.12.3571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173360PMC
December 2019

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia.

BJU Int 2020 Apr 30;125(4):541-552. Epub 2020 Jan 30.

Janssen Medical Affairs, Asia Pacific, Singapore.

Objectives: To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real-world practice in Asia using the United in Fight against prOstate cancer (UFO) registry.

Patients And Methods: We established a multi-national, longitudinal, observational registry of patients with prostate cancer presenting to participating tertiary care hospitals in eight Asian countries. A total of 3636 eligible patients with existing or newly diagnosed high-risk localised prostate cancer (HRL), non-metastatic biochemically recurrent prostate cancer (M0), or metastatic prostate cancer (M1), were consecutively enrolled and are being followed-up for 5 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14980DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187217PMC

[Prediction model for survival in patients with biliary tract cancer: a development and validation study].

Zhonghua Liu Xing Bing Xue Za Zhi 2019 Nov;40(11):1461-1469

Department of Epidemiology and Biostatistics, First Affiliated Hospital, Army Medical University, Chongqing 400038, China.

The aim of the present study was to investigate the survival rate and its prognostic factors for patients with biliary tract cancer, and then a prognostic risk prediction model was constructed to predict the survival probability of patients. A total of 14 005 patients with biliary tract cancer (including gallbladder cancer, extrahepatic bile duct cancer, and ampulla of Vater cancer), who were diagnosed between 2010 and 2015 in the US National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) were included in the development cohort. The prognostic risk factors of biliary tract cancer were investigated using multivariate Cox regression models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2019.11.022DOI Listing
November 2019

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Lancet 2020 01 10;395(10218):132-141. Epub 2019 Dec 10.

Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Pamplona, Spain.

Background: Standard-of-care treatment for patients with newly diagnosed multiple myeloma includes combination therapies for patients who are not eligible for autologous stem-cell transplantation. At the primary analysis for progression-free survival of the phase 3 ALCYONE trial, progression-free survival was significantly longer with daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in patients with transplant-ineligible, newly diagnosed multiple myeloma. Here we report updated efficacy and safety results from a prespecified, interim, overall survival analysis of ALCYONE with more than 36 months of follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)32956-3DOI Listing
January 2020

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

Gut 2020 Aug 4;69(8):1492-1501. Epub 2019 Dec 4.

Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.

Objective: This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint and pre-treatment of sorafenib before initial TACE.

Design: Patients with unresectable hepatocellular carcinoma (HCC) were randomised to TACE plus sorafenib (n=80) or TACE alone (n=76). Patients in the combination group received sorafenib 400 mg once daily for 2-3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable (unTACEable) progression (TTUP), defined as untreatable tumour progression, transient deterioration to Child-Pugh C or appearance of vascular invasion/extrahepatic spread. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2019-318934DOI Listing

Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.

Gastrointest Tumors 2019 Oct 12;6(3-4):92-107. Epub 2019 Sep 12.

Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.

Background: Sorafenib has been established as the standard of care for patients with advanced hepatocellular carcinoma (HCC) since 2007 on the basis of two landmark trials (SHARP and Asia-Pacific). Ten years have passed since then and, despite much research in the field, still no validated real-life prognostic markers are available for HCC patients treated with this drug. Therefore, going through 10 years of research into sorafenib of several Italian Cancer Centers, we conducted a field-practice study aimed at identifying baseline clinical factors that could be significantly associated with overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873043PMC
October 2019

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Lancet 2019 12 14;394(10214):2096-2107. Epub 2019 Nov 14.

Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Background: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)32556-5DOI Listing
December 2019
45.217 Impact Factor

Follow-up after curative resection for gastric cancer: A survey of surgeons across the Asia-Pacific.

Asian J Surg 2020 Jan 31;43(1):389-390. Epub 2019 Oct 31.

Division of General Surgery (Upper Gastrointestinal Surgery), University Surgical Cluster, National University Hospital, Singapore; Division of Surgical Oncology (Upper Gastrointestinal Surgery), National University Cancer Institute, Singapore; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.asjsur.2019.09.011DOI Listing
January 2020
0.758 Impact Factor

Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region.

Hepatol Int 2019 Nov 24;13(6):695-705. Epub 2019 Oct 24.

Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095, Jiefang Avenue, Wuhan, 430030, People's Republic of China.

Background And Aim: Cirrhosis is a controversial determinant of mortality in HBV-related acute-on-chronic liver failure (HBV-ACLF). The present study aimed to explore the effects of cirrhosis and the associated risk factors, especially its complications, on the outcome of HBV-ACLF.

Methods: A prospective-retrospective cohort of 985 patients was identified from the APASL-ACLF Research Consortium (AARC) database and the Chinese Study Group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-019-09992-xDOI Listing
November 2019
2.468 Impact Factor

The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017.

Authors:

Lancet Gastroenterol Hepatol 2020 01 21;5(1):42-54. Epub 2019 Oct 21.

Background: Stomach cancer is a major health problem in many countries. Understanding the current burden of stomach cancer and the differential trends across various locations is essential for formulating effective preventive strategies. We report on the incidence, mortality, and disability-adjusted life-years (DALYs) due to stomach cancer in 195 countries and territories from 21 regions between 1990 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30328-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033564PMC
January 2020

Compendiums of cancer transcriptomes for machine learning applications.

Sci Data 2019 10 8;6(1):194. Epub 2019 Oct 8.

NUS Graduate School for Integrative Sciences & Engineering, National University of Singapore, Singapore, Singapore.

There are massive transcriptome profiles in the form of microarray. The challenge is that they are processed using diverse platforms and preprocessing tools, requiring considerable time and informatics expertise for cross-dataset analyses. If there exists a single, integrated data source, data-reuse can be facilitated for discovery, analysis, and validation of biomarker-based clinical strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41597-019-0207-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783425PMC
October 2019

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.

Pharmacoecon Open 2020 Jun;4(2):235-247

Merck Sharp & Dohme (Asia Pacific), Singapore, Singapore.

Background: Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50% and no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase genomic tumor aberrations. This study was conducted from the perspective of the Hospital Authority in Hong Kong and aimed to evaluate the cost effectiveness of a biomarker (PD-L1) test-and-treat strategy (BTS), in which patients with a TPS ≥ 50% received pembrolizumab and other patients received platinum doublet chemotherapy versus all patients receiving platinum doublet chemotherapy.

Methods: The model used a partitioned survival approach to estimate the incremental cost-effectiveness ratio (ICER) expressed as the cost per quality-adjusted life-year (QALY) gained. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s41669-019-00178-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248157PMC
June 2020
1 Read

Cigarette Smoking and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis.

Pancreas 2019 09;48(8):985-995

From the Department of Gastroenterology, Ruijin Hospital.

Current evidence on cigarette smoking associated with pancreatic cancer mortality is limited. We searched MEDLINE, Web of Science, and Embase databases to identify relevant studies published through January 31, 2018. A random-effects model was used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000001383DOI Listing
September 2019
2 Reads
2.959 Impact Factor

Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?

ESMO Open 2019 17;4(4):e000483. Epub 2019 Jul 17.

Department of Haematology and Oncology, University of Milano, Milan, Italy.

This review article is an overview of the session at the European Society for Medical Oncology (ESMO) Asia 2018 Congress entitled: 'Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?'. The article provides an overview of the session speakers' views on the impact that the lack of accessibility and availability of medicines has on patient outcomes in the treatment of breast cancer, colorectal cancer and lung cancer, responsible for more than one-third of cancer deaths in the Asian region. It also lists the various global policy initiatives that ESMO supports to promote the best cancer care in the Asian and Asia-Pacific region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677966PMC

Addressing cellular heterogeneity in tumor and circulation for refined prognostication.

Proc Natl Acad Sci U S A 2019 09 15;116(36):17957-17962. Epub 2019 Aug 15.

NUS Graduate School for Integrative Sciences & Engineering, National University of Singapore, 117456 Singapore, Singapore;

Despite pronounced genomic and transcriptomic heterogeneity in non-small-cell lung cancer (NSCLC) not only between tumors, but also within a tumor, validation of clinically relevant gene signatures for prognostication has relied upon single-tissue samples, including 2 commercially available multigene tests (MGTs). Here we report an unanticipated impact of intratumor heterogeneity (ITH) on risk prediction of recurrence in NSCLC, underscoring the need for a better genomic strategy to refine prognostication. By leveraging label-free, inertial-focusing microfluidic approaches in retrieving circulating tumor cells (CTCs) at single-cell resolution, we further identified specific gene signatures with distinct expression profiles in CTCs from patients with differing metastatic potential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1907904116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731691PMC
September 2019

Geographical and Temporal Variation in the Incidence and Mortality of Hepato-Pancreato-Biliary Primary Malignancies:1990-2017.

J Surg Res 2020 01 9;245:89-98. Epub 2019 Aug 9.

Departments of Nutrition and Preventive Medicine, Metabolomic and Proteomic Core Facility, Case Western Reserve University, Cleveland, Ohio.

Background: Hepatic, pancreas, and biliary (HPB) cancers pose serious challenges to global health care systems. These malignancies demonstrate great geographical variations with shifting trends over time. The aim of the present study was to determine the recent trends in incidence, prevalence, and mortality of primary HPB malignancies to guide the further development of effective strategies for prevention, screening, and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2019.07.031DOI Listing
January 2020
1 Read

Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.

Cancer 2019 11 12;125(21):3836-3844. Epub 2019 Aug 12.

Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.

Background: The authors hypothesized that epigenetic changes may help to clarify the underlying biologic mechanism linking aspirin use to breast cancer prognosis. To the authors' knowledge, this is the first epidemiologic study to examine whether global methylation and/or tumor promoter methylation of breast cancer-related genes interact with aspirin use to impact mortality after breast cancer.

Methods: Prediagnosis aspirin use was assessed through in-person interviews within a population-based cohort of 1508 women diagnosed with a first primary breast cancer in 1996 and 1997. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147530PMC
November 2019
1 Read

Review of Emerging Japanese Encephalitis Virus: New Aspects and Concepts about Entry into the Brain and Inter-Cellular Spreading.

Pathogens 2019 Jul 26;8(3). Epub 2019 Jul 26.

Platform Anatomy and Department of Oncology, Microbiology and Immunology, University of Fribourg, 1700 Fribourg, Switzerland.

Japanese encephalitis virus (JEV) is an emerging flavivirus of the Asia-Pacific region. More than two billion people live in endemic or epidemic areas and are at risk of infection. Recently, the first autochthonous human case was recorded in Africa, and infected birds have been found in Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/pathogens8030111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789543PMC
July 2019
6 Reads

Hepatoma-derived growth factor participates in Helicobacter Pylori-induced neutrophils recruitment, gastritis and gastric carcinogenesis.

Oncogene 2019 09 22;38(37):6461-6477. Epub 2019 Jul 22.

Center for Neuroscience, National Sun Yat-Sen University, Kaohsiung, Taiwan.

Helicobacter pylori (Hp) infection and overexpression of hepatoma-derived growth factor (HDGF) are involved in gastric carcinogenesis. However, the relationship between Hp-induced gastric diseases and HDGF upregulation is not yet completely clear. This study aimed to elucidate the role of HDGF in Hp-induced gastric inflammation and carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41388-019-0886-3
Publisher Site
http://dx.doi.org/10.1038/s41388-019-0886-3DOI Listing
September 2019
4 Reads

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.

Lung Cancer 2019 08 12;134:174-179. Epub 2019 Jun 12.

Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

Objectives: Tumor programmed death ligand 1 (PD-L1) expression is associated with improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted a global, multicenter, retrospective observational study to determine real-world prevalence of tumor PD-L1 expression in patients with NSCLC.

Materials And Methods: Patients ≥18 years with histologically confirmed stage IIIB/IV NSCLC and a tumor tissue block (≤5 years old) obtained before treatment were identified in 45 centers across 18 countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.06.012DOI Listing

Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea.

Chin Clin Oncol 2019 Jun;8(3):27

Department of Internal Medicine, Clinical Trials Center, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Korea has become the hub of clinical trials in the world. Korea Good Clinical Practice was legislated in 1995, with an amendment in 2001 to adopt International Council of Harmonization (ICH)-Good Clinical Practive (GCP). New Clinical Trial Authorization (CTA) process, which was introduced in 2002 to streamline the regulatory process along with faster study start up, facilitated clinical trials registration in Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2019.06.05DOI Listing

Challenges and insights of early phase oncology drug development in the Asia-Pacific region.

Chin Clin Oncol 2019 Jun;8(3):26

National Cancer Center Hospital, Tokyo, Japan.

Early phase clinical trials form the very foundation of a drug's clinical development. Traditionally, these trials were focused exclusively on dose optimization and toxicities with a broad aim across tumour types in the hope of achieving a signal of response. No real efforts were made to pair patients with best therapies. Read More

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/26545/24274
Publisher Site
http://dx.doi.org/10.21037/cco.2019.06.02DOI Listing
June 2019
2 Reads

Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia.

Br J Haematol 2019 10 17;187(2):227-237. Epub 2019 Jun 17.

Department of Paediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

The treatment of choice for patients with severe aplastic anaemia (SAA) includes immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and ciclosporin A. However, the optimal dose for rabbit ATG has yet to be established. We herein report the first prospective, randomized, multicentre study comparing two doses of rabbit ATG in patients with SAA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16055DOI Listing
October 2019
23 Reads
4.711 Impact Factor

Pan-cancer analysis connects tumor matrisome to immune response.

NPJ Precis Oncol 2019 22;3:15. Epub 2019 May 22.

1NUS Graduate School for Integrative Sciences & Engineering, National University of Singapore, Singapore, Singapore.

Recent sequencing efforts unveil genomic landscapes of tumor microenvironment. A key compartment in this is the extracellular matrix (ECM) and its related components - matrisome. Yet, little is known about the extent to which matrisome pattern is conserved in progressive tumors across diverse cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41698-019-0087-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531473PMC
May 2019
2 Reads

Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005-2015.

Bone Marrow Transplant 2019 12 14;54(12):1973-1986. Epub 2019 May 14.

Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Nagoya, Japan.

Between 2005 and 2015, 138,165 hematopoietic stem cell transplantation (HSCT) were reported in 18 countries/regions in the Asia-Pacific region. In this report, we describe current trends in HSCT throughout the Asia-Pacific region and differences among nations in this region and various global registries. Since 2008, more than 10,000 HSCTs have been recorded each year by the Asia-Pacific Blood and Marrow Transplantation Group Data Center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0554-9DOI Listing
December 2019
14 Reads

Prevalence and risk factors of colorectal cancer in Asia.

Intest Res 2019 Jul 20;17(3):317-329. Epub 2019 May 20.

Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.

Globally, colorectal cancer (CRC) is a substantial public health burden, and it is increasingly affecting populations in Asian countries. The overall prevalence of CRC is reported to be low in Asia when compared with that in Western nations, yet it had the highest number of prevalent cases. This review described the prevalence of CRC in Asia according to the International Agency for Research on Cancer from World Health Organization (WHO) database and summarized its major risk factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5217/ir.2019.00021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667372PMC
July 2019
2 Reads

The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan.

Curr Med Res Opin 2019 10 19;35(10):1745-1750. Epub 2019 Jun 19.

Department of Urology, Sapporo Medical University , Sapporo, Hokkaido , Japan.

Several recent randomized controlled trials (RCTs) in non-metastatic castration resistant prostate cancer (nmCRPC) have demonstrated a significant improvement in metastasis-free survival (MFS); however, an improvement in overall survival (OS) is not reported yet. Since the surrogacy of MFS to OS has not been formally investigated in nmCRPC in Japan, this study evaluated the correlation between MFS and OS among a nmCRPC population in Japan. This is a retrospective longitudinal observational cohort study in patients with nmCRPC using the Japanese Medical Data Vision (MDV) database covering over 20 million patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2019.1619543DOI Listing
October 2019
7 Reads

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Lancet 2019 06 9;393(10189):2404-2415. Epub 2019 May 9.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: A phase 2 trial showed improved progression-free survival for atezolizumab plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who express programmed death-ligand 1 (PD-L1). Here, we report results of IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma.

Methods: In this multicentre, open-label, phase 3, randomised controlled trial, patients with a component of clear cell or sarcomatoid histology and who were previously untreated, were recruited from 152 academic medical centres and community oncology practices in 21 countries, mainly in Europe, North America, and the Asia-Pacific region, and were randomly assigned 1:1 to either atezolizumab 1200 mg plus bevacizumab 15 mg/kg intravenously once every 3 weeks or sunitinib 50 mg orally once daily for 4 weeks on, 2 weeks off. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)30723-8DOI Listing
June 2019
12 Reads

Getting patient blood management Pillar 1 right in the Asia-Pacific: a call for action.

Singapore Med J 2019 May 2. Epub 2019 May 2.

Department of Laboratory Medicine, Inje University Ilsan Paik Hospital, South Korea.

Preoperative anaemia is common in the Asia-Pacific. Iron-deficiency anaemia (IDA) is a risk factor that can be addressed under patient blood management (PBM) Pillar 1, leading to reduced morbidity and mortality. We examined PBM implementation under four different healthcare systems, identified challenges and proposed several measures. Read More

View Article

Download full-text PDF

Source
http://www.smj.org.sg/sites/default/files/RA-2018-047-epub.p
Publisher Site
http://dx.doi.org/10.11622/smedj.2019037DOI Listing
May 2019
12 Reads
0.634 Impact Factor

Comparative evaluation of cerebral gliomas using rCBV measurements during sequential acquisition of T1-perfusion and T2*-perfusion MRI.

PLoS One 2019 24;14(4):e0215400. Epub 2019 Apr 24.

Philips Health Tech Asia Pacific, Minato-ku Tokyo, Japan.

Objective: To assess the inter-technique agreement of relative cerebral blood volume (rCBV) measurements obtained using T1- and T2*-perfusion MRI on 3T scanner in glioma patients.

Methods: A total of 49 adult patients with gliomas underwent both on T1- and T2*-perfusion in the same scanning session, and rCBV maps were estimated using both methods. For the quantitative analysis; Two independent observers recorded the rCBV values from the tumor as well as contralateral brain tissue from both T1- and T2*-perfusion. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215400PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481809PMC
January 2020
3 Reads
3.234 Impact Factor

Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection.

Clin Chim Acta 2019 Aug 20;495:309-317. Epub 2019 Apr 20.

Transfusion Transmitted Diseases Department, National Institute of Immunohaematology (ICMR), 13th Floor, New Multi-storeyed Bldg, KEM Hospital Campus, Parel, Mumbai 400 012, Maharashtra, India. Electronic address:

Background: Hepatocellular carcinoma (HCC) due to Hepatitis B viral (HBV) infection is a major cause in Asia-Pacific countries. Its early detection is of paramount importance using a marker having both sensitivity and specificity. The present study promises diagnostic and prognostic markers by the identification of site-specific glycoforms on Haptoglobin (Hp) using LC-MS/MS and lectin ELISA in liver diseased conditions in HBV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2019.04.072DOI Listing
August 2019
10 Reads

Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial.

BMJ Open 2019 04 20;9(4):e025935. Epub 2019 Apr 20.

Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Introduction: Screening for colorectal cancer (CRC) is effective in reducing the disease burden. However, high-level evidence from randomised controlled trials on the effectiveness of CRC screening modalities is still lacking. We will conduct a large-scale multicentre randomised controlled trial in China to evaluate the effectiveness and cost-effectiveness of different CRC screening strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-025935DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500225PMC
April 2019
2 Reads

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology.

ESMO Open 2019 6;4(2):e000460. Epub 2019 Mar 6.

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Background: Biosimilars can potentially improve the sustainability of cancer care; however, uptake is sometimes limited by safety concerns and a lack of understanding of the concept of extrapolation. The European Society for Medical Oncology (ESMO) conducted a survey to assess the current level of knowledge, understanding and comfort of use of biosimilars among prescribers specialised in oncology.

Methods: A 19-question survey was developed using the SurveyMonkey online platform (https://www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435239PMC
March 2019
19 Reads